argenx SE (LTS:0QW0) Accounts Payable : €461 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is argenx SE Accounts Payable?

argenx SE's Accounts Payable for the quarter that ended in Dec. 2024 was €461 Mil.

argenx SE's quarterly Accounts Payable declined from Jun. 2024 (€261 Mil) to Sep. 2024 (€0 Mil) but then increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€461 Mil).

argenx SE's annual Accounts Payable increased from Dec. 2022 (€197 Mil) to Dec. 2023 (€276 Mil) and increased from Dec. 2023 (€276 Mil) to Dec. 2024 (€461 Mil).

argenx SE Accounts Payable Historical Data

The historical data trend for argenx SE's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Accounts Payable Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

169.60

184.83

196.54

276.33

460.98

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial															276.33	-	260.71	-	460.98

argenx SE Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

argenx SE Accounts Payable Related Terms

Thank you for viewing the detailed overview of argenx SE's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines